Use of $^{99m}$Tc-sestamibi SPECT/CT for indeterminate renal tumours: a pilot diagnostic accuracy study

The increase in cross-sectional imaging across medical disciplines has led to a rise in incidentally-detected renal tumours worldwide [1]. Contemporary imaging cannot reliably distinguish benign from malignant tumours. Renal tumour biopsy is a relatively safe, albeit invasive test with good diagnostic accuracy [2]; however, there is a lack of consensus on its role in the renal tumour diagnostic paradigm [3]. Surgical resection of renal tumours remains the current standard of care, which is considered both diagnostic and therapeutic. However, up to 30% of renal tumours in surgical series are found to be benign [4]. Surgery, with its associated risks, morbidity and costs may represent significant overtreatment of benign tumours [5]. The radiotracer $^{99m}$Tc-sestamibi (MIBI) combined with single-photon emission computed tomography/computed tomography (SPECT/CT) (MIBI-kidney) is an emerging imaging test for non-invasive characterisation of renal tumours [6].

Biological differences in sestamibi radiotracer handling by the tumour cells results in clinically indolent oncocytoma-chromophobe spectrum tumours appearing tracer avid on MIBI-kidney, while clear cell and papillary RCC are relatively photopenic [7]. MIBI-kidney therefore has the potential to address the unmet clinical need for a non-invasive diagnostic tool to risk-stratify renal tumours.

We previously reported findings with examples of radiology images in the first two UK patients to undergo MIBI-kidney in this setting [8]. We now report results from a pilot diagnostic accuracy study of MIBI-kidney against a reference standard of histopathology from surgical specimens or tumour biopsy in what is, to our knowledge, the first UK trial of MIBI-kidney.

The trial was granted ethical approval (Research Ethics Committee [REC] Ref 20/YH/0279) and registered on a clinical trials registry (ISRCTN 23 705 289). From May–October 2021, patients with local renal tumours pending surgery or biopsy, and patients on surveillance for biopsy-confirmed oncocytoma were recruited from the Royal Free Hospital Specialist Centre for Kidney Cancer. Participants with biopsy-confirmed oncocytoma were recruited consecutively at follow-up appointments, while those with indeterminate lesions were purposively sampled to achieve a diverse study population and refine inclusion criteria, e.g., tumour size, stage, concomitant chronic kidney disease, personal history of other primary malignancy. Participants underwent MIBI-kidney according to a previously described protocol [8].

Baseline cross-sectional imaging of the index renal tumour were pseudonymised, and tumour boundaries annotated by a radiologist.

Two independent and experienced nuclear medicine physicians with access to the annotated cross-sectional imaging reviewed the MIBI-kidney studies on two separate occasions. The second review of imaging was performed after a 2-month interval, with studies presented in a different order and assigned a new pseudonymised identification. Nuclear medicine physicians recorded an overall qualitative assessment of tumours as avid, photopenic or indeterminate. A quantitative measure of relative maximum uptake ratio between the tumour and ipsilateral renal parenchyma was also performed. Between first and second review, reporting nuclear medicine clinicians discussed and refined their methods for measurement of quantitative data within the nuclear imaging software (Hermes Medical Solutions). Inter- and intra-rater reliability of the qualitative assessment was assessed using Gwet’s first-order coefficient (AC1) and Cohen’s kappa, and quantitative assessment using Cronbach’s alpha.

Biopsy and surgical specimens were reviewed by an experienced uropathologist blinded to the result of the MIBI-kidney. Oncocytomas were defined as benign, and all RCC subtypes considered malignant.

A total of 20 patients were included; median (interquartile range [IQR]) age 66 (55–70) years and 60% were male. The median (IQR) tumour size was 4.5 (3.5–6.1) cm. Clinical stage was T1a in 40%, T1b in 45%, T2a in 5% and T3a in 10%.

Histopathology results were available for 19 patients (six biopsy, 13 surgical pathology). The final patient commenced active surveillance without a histological diagnosis after two non-diagnostic attempts at biopsy, with tumour size unchanged on imaging at the 6-month follow-up.

Summary results are demonstrated in Fig. 1. Eight MIBI-kidney scans were reported as avid (six oncocytomas, one oncocyctic RCC and one chromophobe RCC), and 12 photopenic (of which 11 had evaluable histology: nine clear cell RCC, two papillary RCC). No tumours were reported as indeterminate on MIBI-kidney imaging. Inter- and intra-rater agreement for qualitative reporting of MIBI-kidney images as
This UK-first MIBI-kidney trial adds to the growing evidence base for non-invasive risk-stratification of indeterminate renal tumours using this test. Our future work will include a multicentre feasibility study to assess barriers and facilitators of set-up at additional sites, development of training materials to interpret MIBI-kidney and a health economic evaluation of MIBI-kidney in the diagnostic pathway for renal tumours in the NHS.

**Acknowledgements**

Hannah Warren receives salary support from The Urology Foundation and the Pan London Cancer Alliance (Royal Marsden Partners, North Central London Cancer Alliance, North East London Cancer Alliance, South East London Cancer Alliance and the NIHR BRCs). We thank the patients who have participated in this pilot study.

**Funding**

Royal Free Charity, St Peter’s Trust, Royal College of Surgeons of England.

**Disclosure of Interests**

None.


1.Division of Surgery and Interventional Science, University College London, London, UK, 2.Royal Free Hospital Specialist Centre for Kidney Cancer, London, UK and 3.Royal Free Hospital Nuclear Medicine Department, London, UK

**References**


The oncological characteristics of non-prostate-specific membrane antigen (PSMA)-expressing primary prostate cancer on preoperative PSMA positron emission tomography/computed tomography

Approximately 5% of patients with D’Amico intermediate- to high-risk, hormone-sensitive prostate cancer (PCa) have a tumour that lacks prostate-specific membrane antigen (PSMA) expression on preoperative positron emission tomography (PET)/CT (non-PSMA\textsubscript{PET}-expressing PCa) [1]. Our recent study showed that patients with non-PSMA\textsubscript{PET}-expressing PCa had similar clinical, pathological, and immunohistochemical characteristics to patients with PSMA\textsubscript{PET}-expressing tumours, suggesting that these patients may have similar prognostic features [1]. In the present study, oncological outcomes (i.e., biochemical recurrence [BCR] and detection of recurrent disease on restaging PSMA PET/CT in case of BCR) of patients with non-PSMA\textsubscript{PET}-expressing PCa were studied.

This study was approved by the local Institutional Review Board (IRBdm19-348). A retrospective, cross-sectional cohort was created consisting of all patients who had hormone-sensitive, D’Amico intermediate- to high-risk PCa, who underwent a preoperative PSMA PET/CT, and who underwent robot-assisted radical prostatectomy (RARP) in a tertiary referral centre between 2016 and March 2020 [1]. The cohort was extended with five additional patients, collected during multidisciplinary oncological board meetings, with non-PSMA\textsubscript{PET}-expressing PCa who underwent RARP between March 2020 and September 2021. Patients underwent PSMA PET/CT with different radiotracers: \textsuperscript{68}Ga-PSMA-11, \textsuperscript{18}F-DCFPyL, \textsuperscript{18}F-PSMA-1007, or \textsuperscript{18}F-JK-PSMA-7. We did not perform subgroup analyses per radiotracer, because this would lower the power of the analyses and the tracers have similar staging accuracy [2]. All preoperative PSMA PET/CT scans were centrally reviewed by experienced nuclear medicine specialists. Non-PSMA\textsubscript{PET}-expressing PCa was defined as no focal tracer uptake in the prostate visually exceeding the background activity of normal prostate tissue, in accordance with Prostate Cancer Molecular Imaging Standardised Evaluation (PROMISE) criteria and the European Association of Nuclear Medicine standardised reporting guidelines for PSMA-PET (E-PSMA) [3,4].

After RARP, patients received oncological follow-up at 4, 8, 12, 18, 24 months after surgery and yearly thereafter. At each visit, the PSA level was measured. We excluded five patients due to missing PSA data. In case of BCR (i.e., PSA level \geq 0.2 ng/mL), a restaging PSMA PET/CT imaging was performed according to European Association of Urology (EAU) guidelines recommendations and interpreted according to local expertise. Pathological data, PSA values, tracer type and clinical reports of restaging PSMA PET/CT were collected.

Differences between patients with non-PSMA\textsubscript{PET}-expressing and PSMA\textsubscript{PET}-expressing PCa were analysed. Categorical variables were analysed with the Fisher’s exact test.

Abbreviations: AC1, Gwet’s first-order coefficient; IQR, interquartile range; MIBI-kidney, \textsuperscript{99m}Tc-sestamibi combined with single-photon emission computed tomography/computed tomography of the kidney.